Pulmonx to Present at BofA Securities 2021 Virtual Health Care Conference

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive lung disease treatments, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:00 am PT / 11:00 am ET. A live and archived webcast will be available in the Investors section of the Pulmonx website.

The company’s Zephyr® Endobronchial Valve and related systems are crucial for treating severe emphysema/COPD patients. The Zephyr Valve is FDA-approved and used in over 25 countries, with more than 80,000 valves deployed.

REDWOOD CITY, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for lung disease, today announced the company will be participating in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 8:00am PT / 11:00am ET.

Interested parties may access a live and archived webcast of the event on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx
Pulmonx Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for lung disease. The Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform, are designed to assess and treat patients with severe emphysema/COPD who despite medical management, are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 80,000 valves used to treat more than 20,000 patients. For more information on the Zephyr Valves, please visit www.MyLungsMyLife.com. For more information on the company, please visit www.Pulmonx.com.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

What is Pulmonx's participation in the BofA Securities 2021 Virtual Health Care Conference?

Pulmonx Corporation will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:00 am PT / 11:00 am ET.

How can I access the Pulmonx conference webcast?

Interested parties can access a live and archived webcast of the conference on the Investors section of the Pulmonx website.

What products does Pulmonx offer for lung disease treatment?

Pulmonx offers the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform for the treatment of severe emphysema/COPD.

What is the significance of the Zephyr Valve in lung disease treatment?

The Zephyr Valve has FDA pre-market approval and is classified as a 'breakthrough device,' indicating its importance in treating patients with severe lung conditions.

How many countries is the Zephyr Valve available in?

The Zephyr Valve is commercially available in over 25 countries.

How many patients have been treated with the Zephyr Valve?

More than 20,000 patients have been treated with over 80,000 Zephyr Valves.